Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
申请人:——
公开号:US20020042097A1
公开(公告)日:2002-04-11
Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallyglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.
OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES
申请人:Tirrell David A.
公开号:US20080160609A1
公开(公告)日:2008-07-03
Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.
Method for producing protein containing nonprotein amino acids
申请人:WAKUNAGA SEIYAKU KABUSHIKI KAISHA
公开号:EP0288087A2
公开(公告)日:1988-10-26
A protein having nonprotein amino acids can be produced by a method which comprises providing a proteinproducing organism with a nutrient containing nonprotein amino acids, cells being cultured to produce the protein in a medium containing the nonprotein amino acids, in which method expression of a gene coding for the protein is induced under conditions in which normal cell growth is suppressed.
The present invention concerns a method for preventing and/or treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine (D-DFMO) or an analog of D-DFMO to the patient. D-DFMO or an analog thereof is administered at a dose of about 0.05 to about 20.0 gm/M
2
/day. D-DFMO or an analog thereof may be administered more than once for the treatment and/or prevention of cancer. Methods of administration as well as compositions and formulations of substantially purified D-DFMO and analogs of D-DFMO are described.